Head and neck cancer in cardiothoracic transplant recipients

Jeffrey D. Pollard, Matthew M. Hanasono, Anthony A. Mikulec, Quynh T. Le, David J Terris

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Introduction: There is an increased incidence of cancer in patients after organ transplantation. We reviewed a large series of cardiothoracic transplant recipients to determine the incidence and natural history of head and neck malignancy. Methods: A total of 1069 heart (n = 855), heart/lung (n = 111), and lung (n = 103) transplants were performed at Stanford University from January 1968 to February 1998. Demographic data, risk factors, and disease course were evaluated in patients who developed cancer. The mean length of follow-up was 8.9 ± 5.2 years. Results: One hundred twenty patients (11.2%) developed 547 non-lymphomatous malignancies. The mean number of malignancies per cancer patient was 4.6. The average time from transplantation to development of cancer was 63.1 months. A total of 50.5% of malignancies presented in the head and neck; 96.4% of these were cutaneous in origin and 3.6% were noncutaneous. Of cutaneous malignancies, 79.3% were squamous cell carcinoma and 15.9% were basal cell carcinoma. Cutaneous malignancies most commonly presented on the scalp, cheek, lip, and neck. Noncutaneous malignancies involved the oral cavity (5), thyroid (4), and parotid (1). Thirteen percent of cutaneous head and neck cancers behaved aggressively, requiring extensive management including radical surgery, radiation, and/or chemotherapy. A total of 34.2% of cancer patients developed metastases and 54.9% of cancer patients died as a direct result of cancer. A total of 68% of cancer patients were smokers and 23.8% had significant alcohol use. Conclusion: Transplant recipients have an increased incidence of cancer presenting in the head and neck. Malignancies in transplant patients behave more aggressively than in the general population. Recognition of this aggressive biological behavior and heightened cancer surveillance should result in improved outcomes.

Original languageEnglish (US)
Pages (from-to)1257-1261
Number of pages5
JournalLaryngoscope
Volume110
Issue number8
DOIs
StatePublished - Jan 1 2000

Fingerprint

Head and Neck Neoplasms
Neoplasms
Neck
Transplant Recipients
Head
Skin
Incidence
Transplants
Lung
Cheek
Basal Cell Carcinoma
Organ Transplantation
Skin Neoplasms
Lip
Scalp
Natural History

Keywords

  • Cancer
  • Head and neck
  • Immunosuppression
  • Squamous cell carcinoma
  • Transplant

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Head and neck cancer in cardiothoracic transplant recipients. / Pollard, Jeffrey D.; Hanasono, Matthew M.; Mikulec, Anthony A.; Le, Quynh T.; Terris, David J.

In: Laryngoscope, Vol. 110, No. 8, 01.01.2000, p. 1257-1261.

Research output: Contribution to journalArticle

Pollard, JD, Hanasono, MM, Mikulec, AA, Le, QT & Terris, DJ 2000, 'Head and neck cancer in cardiothoracic transplant recipients', Laryngoscope, vol. 110, no. 8, pp. 1257-1261. https://doi.org/10.1097/00005537-200008000-00006
Pollard, Jeffrey D. ; Hanasono, Matthew M. ; Mikulec, Anthony A. ; Le, Quynh T. ; Terris, David J. / Head and neck cancer in cardiothoracic transplant recipients. In: Laryngoscope. 2000 ; Vol. 110, No. 8. pp. 1257-1261.
@article{9dbc9acdd31b4e9a99b2fea087069c2d,
title = "Head and neck cancer in cardiothoracic transplant recipients",
abstract = "Introduction: There is an increased incidence of cancer in patients after organ transplantation. We reviewed a large series of cardiothoracic transplant recipients to determine the incidence and natural history of head and neck malignancy. Methods: A total of 1069 heart (n = 855), heart/lung (n = 111), and lung (n = 103) transplants were performed at Stanford University from January 1968 to February 1998. Demographic data, risk factors, and disease course were evaluated in patients who developed cancer. The mean length of follow-up was 8.9 ± 5.2 years. Results: One hundred twenty patients (11.2{\%}) developed 547 non-lymphomatous malignancies. The mean number of malignancies per cancer patient was 4.6. The average time from transplantation to development of cancer was 63.1 months. A total of 50.5{\%} of malignancies presented in the head and neck; 96.4{\%} of these were cutaneous in origin and 3.6{\%} were noncutaneous. Of cutaneous malignancies, 79.3{\%} were squamous cell carcinoma and 15.9{\%} were basal cell carcinoma. Cutaneous malignancies most commonly presented on the scalp, cheek, lip, and neck. Noncutaneous malignancies involved the oral cavity (5), thyroid (4), and parotid (1). Thirteen percent of cutaneous head and neck cancers behaved aggressively, requiring extensive management including radical surgery, radiation, and/or chemotherapy. A total of 34.2{\%} of cancer patients developed metastases and 54.9{\%} of cancer patients died as a direct result of cancer. A total of 68{\%} of cancer patients were smokers and 23.8{\%} had significant alcohol use. Conclusion: Transplant recipients have an increased incidence of cancer presenting in the head and neck. Malignancies in transplant patients behave more aggressively than in the general population. Recognition of this aggressive biological behavior and heightened cancer surveillance should result in improved outcomes.",
keywords = "Cancer, Head and neck, Immunosuppression, Squamous cell carcinoma, Transplant",
author = "Pollard, {Jeffrey D.} and Hanasono, {Matthew M.} and Mikulec, {Anthony A.} and Le, {Quynh T.} and Terris, {David J}",
year = "2000",
month = "1",
day = "1",
doi = "10.1097/00005537-200008000-00006",
language = "English (US)",
volume = "110",
pages = "1257--1261",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Head and neck cancer in cardiothoracic transplant recipients

AU - Pollard, Jeffrey D.

AU - Hanasono, Matthew M.

AU - Mikulec, Anthony A.

AU - Le, Quynh T.

AU - Terris, David J

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Introduction: There is an increased incidence of cancer in patients after organ transplantation. We reviewed a large series of cardiothoracic transplant recipients to determine the incidence and natural history of head and neck malignancy. Methods: A total of 1069 heart (n = 855), heart/lung (n = 111), and lung (n = 103) transplants were performed at Stanford University from January 1968 to February 1998. Demographic data, risk factors, and disease course were evaluated in patients who developed cancer. The mean length of follow-up was 8.9 ± 5.2 years. Results: One hundred twenty patients (11.2%) developed 547 non-lymphomatous malignancies. The mean number of malignancies per cancer patient was 4.6. The average time from transplantation to development of cancer was 63.1 months. A total of 50.5% of malignancies presented in the head and neck; 96.4% of these were cutaneous in origin and 3.6% were noncutaneous. Of cutaneous malignancies, 79.3% were squamous cell carcinoma and 15.9% were basal cell carcinoma. Cutaneous malignancies most commonly presented on the scalp, cheek, lip, and neck. Noncutaneous malignancies involved the oral cavity (5), thyroid (4), and parotid (1). Thirteen percent of cutaneous head and neck cancers behaved aggressively, requiring extensive management including radical surgery, radiation, and/or chemotherapy. A total of 34.2% of cancer patients developed metastases and 54.9% of cancer patients died as a direct result of cancer. A total of 68% of cancer patients were smokers and 23.8% had significant alcohol use. Conclusion: Transplant recipients have an increased incidence of cancer presenting in the head and neck. Malignancies in transplant patients behave more aggressively than in the general population. Recognition of this aggressive biological behavior and heightened cancer surveillance should result in improved outcomes.

AB - Introduction: There is an increased incidence of cancer in patients after organ transplantation. We reviewed a large series of cardiothoracic transplant recipients to determine the incidence and natural history of head and neck malignancy. Methods: A total of 1069 heart (n = 855), heart/lung (n = 111), and lung (n = 103) transplants were performed at Stanford University from January 1968 to February 1998. Demographic data, risk factors, and disease course were evaluated in patients who developed cancer. The mean length of follow-up was 8.9 ± 5.2 years. Results: One hundred twenty patients (11.2%) developed 547 non-lymphomatous malignancies. The mean number of malignancies per cancer patient was 4.6. The average time from transplantation to development of cancer was 63.1 months. A total of 50.5% of malignancies presented in the head and neck; 96.4% of these were cutaneous in origin and 3.6% were noncutaneous. Of cutaneous malignancies, 79.3% were squamous cell carcinoma and 15.9% were basal cell carcinoma. Cutaneous malignancies most commonly presented on the scalp, cheek, lip, and neck. Noncutaneous malignancies involved the oral cavity (5), thyroid (4), and parotid (1). Thirteen percent of cutaneous head and neck cancers behaved aggressively, requiring extensive management including radical surgery, radiation, and/or chemotherapy. A total of 34.2% of cancer patients developed metastases and 54.9% of cancer patients died as a direct result of cancer. A total of 68% of cancer patients were smokers and 23.8% had significant alcohol use. Conclusion: Transplant recipients have an increased incidence of cancer presenting in the head and neck. Malignancies in transplant patients behave more aggressively than in the general population. Recognition of this aggressive biological behavior and heightened cancer surveillance should result in improved outcomes.

KW - Cancer

KW - Head and neck

KW - Immunosuppression

KW - Squamous cell carcinoma

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=0033869404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033869404&partnerID=8YFLogxK

U2 - 10.1097/00005537-200008000-00006

DO - 10.1097/00005537-200008000-00006

M3 - Article

C2 - 10942122

AN - SCOPUS:0033869404

VL - 110

SP - 1257

EP - 1261

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 8

ER -